[{"id":"87c14e4e-dad4-4085-ba55-6c5babc89000","acronym":"","url":"https://clinicaltrials.gov/study/NCT03843775","created_at":"2021-01-18T18:58:38.993Z","updated_at":"2024-07-02T16:35:38.031Z","phase":"Phase 1/2","brief_title":"A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers","source_id_and_acronym":"NCT03843775","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 09/02/2023","primary_completion_date":" 09/02/2023","study_txt":" Completion: 09/02/2023","study_completion_date":" 09/02/2023","last_update_posted":"2023-09-06"},{"id":"e5b2fa7d-d093-4b38-afac-9476bd5a7056","acronym":"MERAIODE","url":"https://clinicaltrials.gov/study/NCT03244956","created_at":"2021-01-18T16:02:03.431Z","updated_at":"2024-07-02T16:36:23.819Z","phase":"Phase 2","brief_title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03244956 - MERAIODE","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-09-28"}]